<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982499</url>
  </required_header>
  <id_info>
    <org_study_id>20160376</org_study_id>
    <nct_id>NCT02982499</nct_id>
  </id_info>
  <brief_title>Biomechanics of Optic Neuropathy</brief_title>
  <official_title>Biomechanics of Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The participant is being asked to be a subject in this research study because the participant&#xD;
      may have a disorder that can cause optic nerve damage and impairment of his/her visual&#xD;
      function which is called optic neuropathies (ON). Optic neuropathy refers to damage to the&#xD;
      optic nerve (a &quot;cable&quot; connecting the eyes and the brain to transmit the visual signals) due&#xD;
      to any cause.In this study, the investigator is using magnetic resonance imaging (MRI) and&#xD;
      ophthalmic measures such as optic coherent tomography(OCT), which are non-invasive imaging&#xD;
      tests to measure the changes in eye globe shape ,the flow of blood and brain fluid. It is&#xD;
      hoped that this study will provide new knowledge that may allow the investigator to better&#xD;
      understand the cause of symptoms associated with optic neuropathy and ways to better monitor&#xD;
      what is happening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal investigator's decision due to lack of resources&#xD;
  </why_stopped>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">March 26, 2018</completion_date>
  <primary_completion_date type="Actual">March 26, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Globe deformation</measure>
    <time_frame>day 1</time_frame>
    <description>Three measures of globe deformation are calculated by using the distance map: 1) optic nerve cupping(ONC), depicting the extent of the nerve head cupping; 2) posterior scleral bowing, depicting the degree of displacement of the posterior wall, and 3) maximal deformation (MD), depicting the combined deformation due to the displacement and the nerve cupping.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intracranial pressure</measure>
    <time_frame>Day 1</time_frame>
    <description>Intracranial pressure will be measured using non invasive MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness</measure>
    <time_frame>Day 1</time_frame>
    <description>Corneal thickness will be measured by corneal pachymetry. After anesthetic numbing drop is placed on the eye, blunt probe will briefly touch the participant's eye to obtain the measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field defect</measure>
    <time_frame>Day 1</time_frame>
    <description>Humphrey Field Analyzer II will be used to acquire the Mean deviation(MD).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Healthy participants will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>optic neuropathy group</arm_group_label>
    <description>Participants with optic neuropathy will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic resonance image (MRI)</intervention_name>
    <description>Radiographic imaging that takes about 30-45 minutes</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>optic neuropathy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography (OCT)</intervention_name>
    <description>Images taken from the back of the eye (retina)</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>optic neuropathy group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Case group: Patients with optic neuropathy who are 18 years or older Control group:&#xD;
        age-matched healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  18 years old and on&#xD;
&#xD;
          -  Patients with optic neuropathy(10) and age controlled healthy subjects(10)&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  For patients: Subjects with history of neurological or ocular disease other than optic&#xD;
             neuropathy and refractory error.&#xD;
&#xD;
          -  For healthy control group: History of systemic disease except hypertension.&#xD;
&#xD;
          -  Pregnant women and prisoners will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byron R Lam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Byron Lam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>Leber optic neuropathy</keyword>
  <keyword>anterior ischemic optic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

